Tissue proteomics outlines AGR2 AND LOX5 as markers for biochemical recurrence of prostate cancer
Oncotarget , Volume 9 - Issue 92 p. 36444- 36456
Although many patients are cured from prostate cancer (PCa) by surgery only, there are still patients who will experience rising prostate-specific antigen (PSA) levels after surgery, a condition known as biochemical recurrence (BCR). Novel protein prognostic markers in PCa tissue might enable finding better treatment for those patients experiencing BCR with a high chance of metastasis. In this study, we aimed to identify altered proteins in prostate cancer tissue, and to evaluate their potential role as prognostic markers. We used two proteomics strategies to analyse 34 prostate tumours (PCa) and 33 normal adjacent prostate (NAP) tissues. An independent cohort of 481 samples was used to evaluate the expression of three proteins: AGR2, FASN and LOX5 as prognostic markers of the disease. Tissue microarray immunohistochemical staining indicated that a low percentage of positive tumour cells for AGR2 (HR (95% CI) = 0.61 (0.43-0.93)), and a low percentage of positive tumour cells for LOX5 expression (HR (95% CI) = 2.53 (1.23-5.22)) are predictors of BCR after RP. In contrast, FASN expression had no prognostic value for PCa.
|Arachidonic acid, Mass spectrometry, Prostate cancer|
|This work was funded by the European Commission 7th Framework Programme; grant id fp7/238278 - Prostate Research Organizations-Network of Early Stage Training (PRO-NEST)|
|Organisation||Department of Neurology|
Rodríguez-Blanco, G. (Giovanny), Zeneyedpour, L, Duijvesz, D, Hoogland, A.M, Verhoef, E.I, Kweldam, C.F, … Luider, T.M. (2018). Tissue proteomics outlines AGR2 AND LOX5 as markers for biochemical recurrence of prostate cancer. Oncotarget, 9(92), 36444–36456. Retrieved from http://hdl.handle.net/1765/112592